This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Conflicted on These Healthcare Names: InMode (INMD), Achieve Life Sciences (ACHV) and BioNTech SE (BNTX)

Tipranks - Tipranks - Fri May 22, 6:36AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on InMode (INMD), Achieve Life Sciences (ACHV) and BioNTech SE (BNTX).

Meet Samuel – Your Personal Investing Prophet

InMode (INMD)

In a report released today, Caitlin Roberts from Canaccord Genuity reiterated a Hold rating on InMode, with a price target of $15.00. The company’s shares closed last Wednesday at $14.02.

According to TipRanks.com, Roberts is a 3-star analyst with an average return of 3.9% and a 44.3% success rate. Roberts covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Zimmer Biomet Holdings, and Smith & Nephew Snats. ;'>

Currently, the analyst consensus on InMode is a Hold with an average price target of $15.75, which is a 14.5% upside from current levels. In a report issued on May 9, TipRanks – Google also downgraded the stock to Hold with a $15.00 price target.

See today’s best-performing stocks on TipRanks >>

Achieve Life Sciences (ACHV)

In a report released today, Gary Nachman from Canaccord Genuity assigned a Buy rating to Achieve Life Sciences, with a price target of $13.00. The company’s shares closed last Wednesday at $4.57.

According to TipRanks.com, Nachman is a 2-star analyst with an average return of 0.1% and a 46.4% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Scholar Rock Holding, and ADMA Biologics. ;'>

Achieve Life Sciences has an analyst consensus of Strong Buy, with a price target consensus of $13.20, which is a 194.0% upside from current levels. In a report issued on May 12, Maxim Group also maintained a Buy rating on the stock with a $10.00 price target.

BioNTech SE (BNTX)

Canaccord Genuity analyst John Newman assigned a Buy rating to BioNTech SE today and set a price target of $158.00. The company’s shares closed last Wednesday at $90.36.

According to TipRanks.com, Newman is a 4-star analyst with an average return of 3.2% and a 41.8% success rate. Newman covers the Healthcare sector, focusing on stocks such as BridgeBio Oncology Therapeutics, Allogene Therapeutics, and Atara Biotherapeutics. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for BioNTech SE with a $131.50 average price target, representing a 49.6% upside. In a report issued on May 6, Wells Fargo also maintained a Buy rating on the stock with a $140.01 price target.

Read More on INMD:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).